Search / 16 results found

from
to
  • Updated

World's first voice intelligence solution embedded in major service provider networks and UC solutions like Cisco Webex, Microsoft Teams and Zoom - eliminates need for costly hardware and servicesPurpose-built for compliance teams to specify, manage, record, store, and analyze all communications - voice calls, chat, presentations and moreAvailable today globally with immediate provisioning

  • Updated

World's first voice intelligence solution embedded in major service provider networks and UC solutions like Cisco Webex, Microsoft Teams and Zoom - eliminates need for costly hardware and servicesPurpose-built for compliance teams to specify, manage, record, store, and analyze all communications - voice calls, chat, presentations and moreAvailable today globally with immediate provisioning

  • Updated

Answers global demand for unified call recording and voice intelligence across any communications end-point with the world's most comprehensive and advanced product familyCreates seamless ability to enrich any conversation with AI and share with business applicationsSimple, easy to deploy, flexible monthly and annual plansNew solutions designed specifically for compliance managers and teams

  • Updated

Answers global demand for unified call recording and voice intelligence across any communications end-point with the world's most comprehensive and advanced product familyCreates seamless ability to enrich any conversation with AI and share with business applicationsSimple, easy to deploy, flexible monthly and annual plansNew solutions designed specifically for compliance managers and teams

  • Updated

SAN ANTONIO, May 13, 2021 /PRNewswire/ -- CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced its flagship COBRA PzF NanoCoated Coronary Stent (NCS) achieved exceptional long-term ischemic safety of 0% definite and probable stent thrombosis (ST) and low ischemia-driven target lesion revascularization (ID-TLR) of 7.8% for its non-angiographic cohort at five years.1 Results conclude the company's global, multicenter PzF SHIELD IDE clinical trial of highly complex patients undergoing percutaneous coronary intervention (PCI). The study met its primary and secondary endpoints at 9 months, demonstrating an excellent safety profile with 0% ST and low, 4.6% ID-TLR with a minimum of 1-month DAPT therapy and was the basis for the stent's FDA approval in 2017.2,3

  • Updated

HOUSTON, April 29, 2021 /PRNewswire/ -- Bristow Group Inc. (NYSE: VTOL) today announced a three-year contract extension until August 2024 with Aker BP to support air transportation crew change services for their operations in the Norwegian continental shelf.

  • Updated

DALLAS, April 8, 2021 /PRNewswire/ -- Dynata, the world's largest first part data and insights platform, today released Global Consumer Trends: The Green Economy, a global look at emerging economy surrounding green energy and sustainability. The report, part of Dynata's ongoing Global Consumer Trends research series, also revealed that nearly half of consumers worldwide believe that whoever leads the Green Economy will lead the world.